Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review.

J Cancer Res Clin Oncol · 2024 · PMC10847200 · PMID 38319412

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in a phase II KEYNOTE-224 trial, overall survival and progression-free survival of patients treated with pembrolizumab did not reach statistical significance according to the pre-specified criteria (Zhu et al. 2018 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.